Journal of Substance Abuse Treatment
Volume 28, Issue 3 , Pages 265-272 , April 2005

Characteristics of older opioid maintenance patients

Received 19 July 2004 ,Revised 10 December 2004 ,Accepted 11 January 2005.

References 

  1. Addiction Treatment Forum. The further "graying of methadone". Addiction Treatment Forum. 2003, winter;12:4–5
  2. Barrick C, Connors GJ. Relapse prevention and maintaining abstinence in older adults with alcohol-use disorders. Drugs & Aging. 2002;19:583–594
  3. Blow F. Substance abuse among older adults. Rockville, MD: U.S. Department of Health and Human Services; 1998;
  4. Brooner RK, King VL, Kidorf M, Schmidt CW, Bigelow GE. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Archives of General Psychiatry. 1997;54:71–80
  5. Brown LS, Hickson MJ, Ajuluchukwu DC, Bailey J. Medical disorders in a cohort of New York city drug abusers: much more than HIV disease. Journal of Addictive Diseases. 1993;12:11–27
  6. Brunet A, Boucher C, Boyer R. Social desirability in the assessment of trauma. Psychological Reports. 1996;79:511–514
  7. Cacciola JS, Alterman AI, Rutherford MJ, McKay JR, Mulvaney FD. The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug and Alcohol Dependence. 2001;61:271–280
  8. Clemmey P, Brooner RK, Chutuape MA, Kidorf M, Stitzer M. Smoking habits and attitudes in a methadone maintenance treatment population. Drug and Alcohol Dependence. 1997;44:123–132
  9. Dufour MC, Archer L, Gordis E. Alcohol and the elderly. Clinics in Geriatric Medicine. 1992;8:127–141
  10. Fingerhood MI, Jasinski DR, Sullivan JT. Prevalence of hepatitis C in a chemically dependent population. Archives of Internal Medicine. 1993;153:2025–2030
  11. Gfroerer J, Penne M, Pemberton M, Folsom R. Substance abuse treatment need among older adults in 2020: the impact of the aging baby-boom cohort. Drug and Alcohol Dependence. 2003;69:127–135
  12. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. American Journal of Public Health. 2001;91:42–46
  13. Haverkos HW. Infectious diseases and drug abuse. Prevention and treatment in the drug abuse treatment system. Journal of Substance Abuse Treatment. 1991;8:269–275
  14. In:  Higgins S,  Silverman K editor. Motivating behavioral change among illicit-drug abusers. Washington, DC: American Psychological Association; 1999;
  15. Isaacs SL, Schroeder SA. Class—the ignored determinant of the nation's health. New England Journal of Medicine. 2004;351:1137–1142
  16. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry. 1994;51:8–19
  17. Khantzian EJ, Treece C. DSM-III psychiatric diagnosis of narcotic addicts. Recent findings. Archives of General Psychiatry. 1985;42:1067–1071
  18. In:  Korper SP,  Council CL editor. Substance use by older adults: Estimates of future impact on the treatment system. Rockville, MD: National Clearinghouse for Alcohol and Drug Information; 2003;(Analytic Series: A-21.)
  19. Kosten TR, Rounsaville BJ, Kleber HD. Concurrent validity of the Addiction Severity Index. Journal of Nervous and Mental Diseases. 1983;171:606–610
  20. McHorney CA, Ware JE, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Medical Care. 1994;32:40–66
  21. McHorney CA, Ware JE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care. 1993;31:247–263
  22. McLellan AT, Luborsky L, Cacciola J, Griffith JE, Evans F, Barr HL, et al. New data from the Addiction Severity Index: Reliability and validity in three centers. Journal of Nervous and Mental Disease. 1985;173:412–423
  23. McLellan AT, Luborsky L, Woody GE, O'Brien CP. Improved diagnostic evaluation instrument for substance abuse patients—Addiction Severity Index. Journal of Nervous and Mental Disease. 1980;168:26–33
  24. Menninger JA. Assessment and treatment of alcoholism and substance-related disorders in the elderly. Bulletin of the Menninger Clinic. 2002;66:166–183
  25. Milby JB, Sims MK, Khuder S, Schumacher JE, Huggins N, McLellan AT, et al. Psychiatric comorbidity: Prevalence in methadone maintenance treatment. American Journal of Drug and Alcohol Abuse. 1996;22:95–107
  26. Neumark YD, Van Etten ML, Anthony JC. “Drug dependence” and death: Survival analysis of the Baltimore ECA sample from 1981 to 1995. Substance Use and Misuse. 2000;35:313–327
  27. Norris FH. Epidemiology of trauma: Frequency and impact of different potentially traumatic events on different demographic groups. Journal of Consulting and Clinical Psychology. 1992;60:409–418
  28. Parra GR, O'Neill SE, Sher KJ. Reliability of self-reported age of substance involvement onset. Psychology of Addictive Behaviors. 2003;17:211–218
  29. Reid MC, Anderson PA. Geriatric substance use disorders. Medical Clinics of North America. 1997;81:999–1016
  30. Rigler, S. K. (2000). Alcoholism in the elderly. American Family Physician, 61, 1710-6, 1883-4, 1887-8 passim.
  31. Robins LN, Helzer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke JD, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Archives of General Psychiatry. 1984;41:949–958
  32. Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy R. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003;289:2370–2378
  33. Saxby BK, Harrington F, McKeith IG, Wesnes K, Ford GA. Effects of hypertension on attention, memory, and executive function in older adults. Health Psychology. 2003;22:587–591
  34. Selby MJ, Azrin RL. Neuropsychological functioning in drug abusers. Drug and Alcohol Dependence. 1998;50:39–45
  35. Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Archives of General Psychiatry. 1992;49:624–629
  36. Strain EC, Brooner RK, Bigelow GE. Clustering of multiple substance use and psychiatric diagnoses in opiate addicts. Drug and Alcohol Dependence. 1991;27:127–134
  37. Umbricht-Schneiter A, Ginn DH, Pabst KM, Bigelow GE. Providing medical care to methadone clinic patients: Referral vs on-site care. American Journal of Public Health. 1994;84:207–210
  38. Ware JE, Kosinski M, Dewey JE. How to Score Version 2 of the SF-36 Health Survey. Lincoln, RI: Quality Metric Inc.; 2000;
  39. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care. 1992;30:473–483
  40. Williams JB, Gibbon M, First MB, Spitzer RL, Davies M, Borus J, et al. The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability. Archives of General Psychiatry. 1992;49:630–636

PII: S0740-5472(05)00019-X

doi: 10.1016/j.jsat.2005.01.007

Journal of Substance Abuse Treatment
Volume 28, Issue 3 , Pages 265-272 , April 2005

Article Tools